Cyclin-Dependent Kinase inhibitors currently exhibits a strong pipeline with 24 drug candidates by P&S Market Research.
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells.
These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Explore Report at: www.psmarketresearch.com/market-an…pipeline-analysis
According to the research findings, most of the drug candidates of CDK inhibitors therapeutics pipeline are being developed to be administered by oral route.
USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.
Explore Report at: www.psmarketresearch.com/market-an…sis/report-sample
Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!